SUMMARY Multiple valve replacement with pericardial xenografts (sizes 17 to 31) was undertaken in 76 patients. The incidence of early and late deaths was 10-5 and 3 9 per cent, respectively. Actuarially it is predicted that 94 7+3-9 per cent of hospital survivors will be alive at three and a half years after valve replacement. Though long-term anticoagulants were not used, thrombotic valve obstruction was not seen in this series. A systemic embolus occurred early in one case only (0 95 episodes/100 patient years). Mechanical dysfunction of the pericardial xenograft has not been seen.
patients are shown in Table 2 . All valve replacement operations were performed using total body hypo- Rhythm: Sinus 20 
26* Atrial fibrillation 56 74
Previous cardiac surgery 26 34 Valve replacement and repair 6 Closed mitral valvotomy 19 Mitral and aortic valve replacement 1 Figures in parentheses represent the number of valves of each type in patients subjected to reinvestigation.
thermia (20 to 26°C) with cold cardioplegia and topical hypothermia. The temperature of the interventricular septum was maintained by these combined measures between 16 and 18°C. The annulus diameter of the pericardial xenografts implanted ranged from 17 to 31 mm (Table 3) . Annuloplastic procedures were not performed irrespective of the size of the aortic root. At the time of valve replacement, 39 additional surgical interventions were undertaken in 33 patients, as shown in Table 4 . All patients received oral sodium warfarin from the second or third postoperative day for a period of four to six weeks. The prothrombin time was maintained around or below twice normal. Long-term anticoagulation was not used.
All patients were seen at six-monthly intervals after operation. Seven patients were reinvestigated between eight and 21 months (mean 12 months) postoperatively. Three had had mitral and tricuspid, one mitral and aortic, and three mitral, aortic, and tricuspid valve replacement. The criteria for selection for reinvestigation were the availability of complete preoperative haemodynamic and angiographic data and the informed consent of the patients. The annulus diameters of the pericardial xenografts investigated are shown in Table 3 . The actuarial analysis predicts that 94'7 ±3'9 per cent of hospital survivors will be alive at one and at three and a half years after valve replacement (Fig. 1) .
The 65 long-term survivors have been followed for a total of 1257 patient months, with a mean individual follow-up of 19-3 months (range three to 42). (Fig. 1) .
CLINICAL DATA Forty-eight of the 65 long-term survivors had been in New York Heart Association class III and 12 in class IV preoperatively; 5 had been in class II. At the latest postoperative visit 39 were now in class I and the remaining 26 were in class II (Fig. 2) . The preoperative cardiothoracic ratio of the entire group was 62-3 ±1-22 per cent and it had decreased significantly to 57-5 ± 1-0 per cent (p<0.001) at the latest postoperative visit. On analysis of the three subgroups this high level of significance applied only to those patients with mitral and aortic valve replacement (p < 0.001), though the other two subgroups also showed significant reductions in cardiothoracic ratio (Fig. 2) .
There were no changes in the proportion of patients with atrial fibrillation (74%) and with sinus rhythm (26%) between the preoperative and the latest postoperative visit. No significant change was noted in either left or right ventricular forces in the electrocardiogram.
HAEMODYNAMIC DATA
The results of the haemodynamic investigations are summarised in Table 5 Actuarially it is predicted that 94 7 ±3-9 per cent of hospital survivors will be alive at one and at three and a half years after valve replacement (Fig. 1) . This actuarial survival rate is similar to the figures reported with either mechanical prostheses"3-'6 18 21 or porcine valves'6 17 20 22 for similar periods of follow-up. Fig. 3 shows, for comparison, the survival curves of patients having isolated aortic or mitral valve replacement with pericardial xenografts. Though the duration of follow-up of patients with multiple valve replacement is shorter, the survival curve of this group (for the initial three and a half postoperative years) is comparable to the survival of patients with single valve replacement. This observation is at variance with other reports'5 21 22 which show a lower survival ratio in patients with multiple valve replacement.
Thrombotic valve obstruction, which has been described with mechanical prostheses'8 23 and porcine valves,2' 22 24 has not been encountered with the pericardial xenograft, either with single valve, or in the present series of multiple valve replacement, though long-term anticoagulation was not used. The absence of thrombotic obstruction is the more significant in the present series as it includes 22 patients in whom the tricuspid valve has been replaced. Even though 74 per cent of patients were in chronic atrial fibrillation pre-and postoperatively, there was only one transient embolic event (0-95 episodes/100 patient years) in this series and it occurred on the second postoperative day in a patient with triple valve replacement. Actuarially it is predicted that 98-3 i 1 7 per cent of our patients with multiple valve replacement will be free from embolism three and a half years after operation (Fig. 1) . The embolic rate in this series is lower than that reported from patients having multiple valve replacement with either mechanical prostheses9-'4 16 18 or porcine valves.'7 20 22 This low incidence of embolism is comparable with that encountered in patients having single valve replacement with pericardial xenografts and observed for a similar duration of follow-up, as shown in Fig. 4 The incidence of endocarditis in this series (19 episodes/100 patient years) is similar to that reported with other types of valve replacement.'2-'4 16 20 All patients derived considerable benefit from the operation, 60 per cent being in New York Heart Association class I and 40 per cent in class II at the most recent follow-up.
The haemodynamic investigations performed in seven patients at a mean of 12 months after operation showed normal cardiac outputs at rest. The pulmonary wedge and left ventricular enddiastolic pressures did not return to normal levels, which is not unexpected as all these patients had been in New York Heart Association class III and IV preoperatively. Similar observations have been made by others.'5 19 21 The peak systolic and mean diastolic gradients across the aortic and atrioventricular valves were similar to those which have been obtained in patients with isolated aortic or mitral valve replacement with pericardial xenografts.4-The calculated surface areas of the aortic pericardial xenografts were 1 cm2 or larger. Thus complicated annuloplastic procedures are unnecessary in patients with a small aortic annulus because of the optimal ratio of implantation diameter to orifice area of the pericardial xenograft valve. The mitral and tricuspid xenografts had areas around 2 cm2. These data from a small number of patients having multiple valve replacement are similar to those obtained in a larger series of patients with isolated aortic or mitral valve replacement with pericardial xenografts.5 6 For this reason catheterisation of a larger number of patients with multiple replacements was not considered at this stage. Table 6 summarises the incidence of major complications in our entire experience with 590 pericardial xenografts inserted in 506 patients. Mechanical dysfunction of the pericardial xenograft In conclusion, this preliminary study of patients with multiple valve replacement has shown a very low propensity for embolism in the absence of longterm anticoagulation and superior haemodynamic performance of the pericardial xenograft when compared with other tissue values.15 20 Continuous, systematic follow-up of patients with pericardial xenografts will provide the necessary data on progressively longer periods of observation.
